| Vivus (VVUS) rocketed over 37 percent during trading today after C.E. Unterberg, Towbin raised its rating to "strong buy," pointing to important progress trials of the Vivus product Allista for the treatment of female sexual dysfunction. 
 CONTACT: VIVUS Inc.
 Richard Walliser, 650/934-5200
 ir@vivus.com
 www.vivus.com
 or
 Lippert/Heilshorn & Associates Inc.
 Bruce Voss, 310/691-7100 (Investor Contacts)
 bvoss@lhai.com
 Jody Cain, 310/691-7100 (Investor Contacts)
 jcain@lhai.com
 Elissa Grabowski, 212/838-3777 (Media Contact)
 egrabowski@lhai.com
 www.lhai.com
 |